21 November 2025 : Clinical Research
Survival and Cost Analysis of Surgical Mitral Valve Replacement With Different Prostheses: A Nationwide Cohort Study in Taiwan
Yu-san Chien
CDEF 1,2*, Ching-hu Chung ABCD 2, Jiun-yi Li ADE 2,3,4
DOI: 10.12659/MSM.950020
Med Sci Monit 2025; 31:e950020
Table 3 Multivariate logistic regression analysis of risk factors for mortality after surgical mitral valve replacement.
| Before PSM | After PSM (MV vs DV) | After PSM (PV vs DV) | ||||
|---|---|---|---|---|---|---|
| HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
| Older bioprosthetic porcine valve (PV) | 1.20 (1.13–1.29) | <0.001 | . | . | . | . |
| Durable valve (DV) | 0.63 (0.52–0.76) | <0.001 | 0.55 (0.45–0.67) | <0.001 | 0.53 (0.44–0.64) | <0.001 |
| Age | 1.039 (1.036–1.042) | <0.001 | 1.040 (1.036–1.044) | <0.001 | 1.037 (1.033–1.041) | <0.001 |
| Female | 0.82 (0.77–0.87) | <0.001 | 0.78 (0.72–0.85) | <0.001 | 0.86 (0.79–0.93) | <0.001 |
| Reginal hospital | 1.02 (0.95–1.09) | 0.288 | 1.06 (0.95–1.17) | 0.296 | 0.99 (0.92–1.09) | 0.971 |
| Comorbidity | ||||||
| Myocardial infarction | 1.63 (1.51–1.77) | <0.001 | 1.55 (1.37–1.75) | <0.001 | 1.73 (1.56–1.92) | <0.001 |
| Congestive heart failure | 1.16 (1.08–1.25) | <0.001 | 1.25 (1.13–1.39) | <0.001 | 1.09 (0.99–1.20) | 0.095 |
| Peripheral vascular disease | 1.30 (1.16–1.47) | <0.001 | 1.34 (1.12–1.61) | 0.001 | 1.32 (1.13–1.54) | <0.001 |
| Cerebrovascular disease | 1.18 (1.09–1.27) | <0.001 | 1.14 (1.02–1.28) | 0.021 | 1.21 (1.01–1.34) | <0.001 |
| Dementia | 1.28 (1.05–1.56) | 0.014 | 1.85 (1.28–2.68) | 0.001 | 1.21 (0.97–1.52) | 0.090 |
| Chronic pulmonary disease | 1.04 (0.98–1.11) | 0.164 | 1.07 (0.98–1.16) | 0.170 | 1.02 (0.94–1.11) | 0.609 |
| Rheumatic disease | 1.01 (0.85–1.20) | 0.904 | 1.04 (0.81–1.34) | 0.769 | 0.99 (0.79–1.25) | 0.937 |
| Peptic ulcer disease | 0.99 (0.93–1.06) | 0.853 | 1.05 (0.94–1.16) | 0.404 | 0.94 (0.86–1.09) | 0.205 |
| Mild liver disease | 1.09 (1.00–1.17) | 0.043 | 1.12 (0.99–1.25) | 0.059 | 1.06 (0.95–1.18) | 0.334 |
| Diabetes without complications | 1.32 (1.23–1.42) | <0.001 | 1.43 (1.28–1.59) | <0.001 | 1.24 (1.13–1.37) | <0.001 |
| Diabetes with chronic complications | 1.32 (1.19–1.46) | <0.001 | 1.51 (1.28–1.78) | <0.001 | 1.23 (1.08–1.40) | 0.002 |
| Paraplegia and hemiplegia | 1.06 (0.87–1.29) | 0.590 | 1.12 (0.84–1.50) | 0.432 | 1.00 (0.77–1.31) | 0.985 |
| Renal disease | 1.83 (1.70–1.97) | <0.001 | 2.00 (1.78–2.25) | <0.001 | 1.76 (1.60–1.94) | <0.001 |
| Cancer | 1.26 (1.12–1.44 | <0.001 | 1.47 (1.22–1.78) | <0.001 | 1.21 (1.04–1.40) | 0.013 |
| Moderate or severe liver disease | 2.62 (1.91–3.59) | <0.001 | 2.01 (1.24–3.26) | 0.005 | 3.13 (2.06–4.75) | <0.001 |
| Metastatic carcinoma | 1.21 (0.83–1.76) | 0.317 | 1.18 (0.61–2.31) | 0.624 | 1.20 (0.77–1.87) | 0.428 |
| AIDS/HIV | 4.26 (1.05–6.11) | 0.039 | 4.26 (1.58–11.48) | 0.004 | 1.75 (0.56–5.49) | 0.335 |